DESSOLVE China is a prospective, single-blind, multi-center, randomized, controlled, registration clinical trial on the efficacy and safety of sirolimus-eluting stent (MiStent® System) in the treatment of patients with coronary heart disease comparing angiographic measures at nine months and clinical outcomes at 12 months. The trial will enroll 428 patients in a 1:1 ratio (214 cases enrolled into each group, MiStent and the control, TIVOLI) in up to 23 clinical sites.
Prof. Yaling Han, General Hospital, Shenyang Military Region, Shenyang, China
Prof. Yuejin Yang, Cardiovascular Institute / Fu Wai Hospital, Beijing, China (co-principal investigator)
Prof. Xu Bo, Cardiovascular Institute / Fu Wai Hospital, Beijing, China (co-principal investigator)
More information on the DESSOLVE C trial can be found here.